Literature DB >> 31513782

Establishment of ornithine transcarbamylase deficiency-derived primary human hepatocyte with hepatic functions.

Shan Su1, Cristina Di Poto1, Alexander H Kroemer2, Wanxing Cui2, Rabindra Roy1, Xuefeng Liu3, Habtom W Ressom4.   

Abstract

A long-term hepatocyte culture maintaining liver-specific functions is very essential for both basic research and the development of bioartificial liver devices in clinical application. However, primary hepatocytes rapidly lose their proliferation and hepatic functions over a few days in culture. This work is to establish an ornithine transcarbamylase deficiency (OTCD) patient-derived primary human hepatocyte (OTCD-PHH) culture with hepatic functions for providing an in vitro cell model. Liver tissue from an infant with OTCD was dispersed into single cells. The cells were cultured using conditional reprogramming. To characterize the cells, we assessed activities and mRNA expression of CYP3A4, 1A1, 2C9, as well as albumin and urea secretion. We found that the OTCD-PHH can be subpassaged for more than 15 passages. The cells do not express mRNA of fibroblast-specific maker, whereas they highly express markers of epithelial cells and hepatocytes. In addition, the OTCD-PHH retain native CYP3A4, 1A1, 2C9 activities and albumin secretion function at early passages. The OTCD-PHH at passages 2, 6, 9 and 13 have identical DNA fingerprint as the original tissue. Furthermore, under 3D culture environment, low urea production and hepatocyte marker staining of the OTCD-PHH were detected. The established OTCD-PHH maintain liver-specific functions at early passages and can be long-term cultured in vitro. We believe the established long-term OTCD-PHH culture is highly relevant to study liver diseases, particularly in infants with OTCD.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CYP450 activity; Long-term culture; Ornithine transcarbamylase deficiency (OTCD); Primary human hepatocyte (PHH)

Year:  2019        PMID: 31513782      PMCID: PMC6786762          DOI: 10.1016/j.yexcr.2019.111621

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  19 in total

1.  Perfusion-based microfluidic device for three-dimensional dynamic primary human hepatocyte cell culture in the absence of biological or synthetic matrices or coagulants.

Authors:  Vasiliy N Goral; Yi-Cheng Hsieh; Odessa N Petzold; Jeffery S Clark; Po Ki Yuen; Ronald A Faris
Journal:  Lab Chip       Date:  2010-11-08       Impact factor: 6.799

2.  Isolation and culture of primary hepatocytes from resected human liver tissue.

Authors:  Edward L Lecluyse; Eliane Alexandre
Journal:  Methods Mol Biol       Date:  2010

Review 3.  Bioartificial liver systems: current status and future perspective.

Authors:  Jung-Keug Park; Doo-Hoon Lee
Journal:  J Biosci Bioeng       Date:  2005-04       Impact factor: 2.894

4.  Efficient procurement of epithelial stem cells from human tissue specimens using a Rho-associated protein kinase inhibitor Y-27632.

Authors:  Atsushi Terunuma; Renuka Pudi Limgala; Christine J Park; Isha Choudhary; Jonathan C Vogel
Journal:  Tissue Eng Part A       Date:  2010-04       Impact factor: 3.845

Review 5.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors.

Authors:  S Rendic; F J Di Carlo
Journal:  Drug Metab Rev       Date:  1997 Feb-May       Impact factor: 4.518

Review 6.  Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity.

Authors:  Qin Meng
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-06       Impact factor: 4.481

Review 7.  Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation.

Authors:  E L LeCluyse
Journal:  Eur J Pharm Sci       Date:  2001-07       Impact factor: 4.384

8.  Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens.

Authors:  Xuefeng Liu; Ewa Krawczyk; Frank A Suprynowicz; Nancy Palechor-Ceron; Hang Yuan; Aleksandra Dakic; Vera Simic; Yun-Ling Zheng; Praathibha Sripadhan; Chen Chen; Jie Lu; Tung-Wei Hou; Sujata Choudhury; Bhaskar Kallakury; Dean G Tang; Thomas Darling; Rajesh Thangapazham; Olga Timofeeva; Anatoly Dritschilo; Scott H Randell; Christopher Albanese; Seema Agarwal; Richard Schlegel
Journal:  Nat Protoc       Date:  2017-01-26       Impact factor: 13.491

Review 9.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

Review 10.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

View more
  4 in total

Review 1.  Conditional reprogramming: Modeling urological cancer and translation to clinics.

Authors:  Wei Liu; Lingao Ju; Songtao Cheng; Gang Wang; Kaiyu Qian; Xuefeng Liu; Yu Xiao; Xinghuan Wang
Journal:  Clin Transl Med       Date:  2020-06-05

Review 2.  Conditional cell reprogramming for modeling host-virus interactions and human viral diseases.

Authors:  Xuefeng Liu; Abdul M Mondal
Journal:  J Med Virol       Date:  2020-06-16       Impact factor: 2.327

Review 3.  Conditional Cell Reprogramming in Modeling Digestive System Diseases.

Authors:  Ruihua Zhao; Rui Li; Tianqi An; Xuefeng Liu
Journal:  Front Cell Dev Biol       Date:  2021-06-03

Review 4.  Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks.

Authors:  Nancy Palechor-Ceron; Ewa Krawczyk; Aleksandra Dakic; Vera Simic; Hang Yuan; Jan Blancato; Weisheng Wang; Fleesie Hubbard; Yun-Ling Zheng; Hancai Dan; Scott Strome; Kevin Cullen; Bruce Davidson; John F Deeken; Sujata Choudhury; Peter H Ahn; Seema Agarwal; Xuexun Zhou; Richard Schlegel; Priscilla A Furth; Chong-Xian Pan; Xuefeng Liu
Journal:  Cells       Date:  2019-10-27       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.